INOVIO

DNA MEDICINE:
HARNESSING THE POWER OF *IN VIVO* PROTEIN PRODUCTION

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids — small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.

Optimized design and delivery, teaching the body to fight disease



Targeted Therapies, T Cell Driven Immune Responses

INOVIO can design plasmids to teach the body's cells to produce a wide range of proteins, including antigens to elicit a specific immune response, monoclonal antibodies to fight a specific pathogen, or therapeutic proteins to replace defective or missing proteins in the body. Our versatile platform is able to generate antigen-targeted humoral and cellular immune responses, including antigen-specific cytotoxic or killer T cell responses that are important for fighting cancer and viral infections.

INVESTMENT HIGHLIGHTS

- BLA for INO-3107 advancing; Oct 30, 2026 target PDUFA date
- Commercial preparations for INO-3107 underway in anticipation of potential product launch
- Pipeline progress through collaborations & strategic partnerships
  - Positive topline results reported from Phase 3 trial for VGX-3100 in cervical dysplasia patients by ApolloBio, INOVIO's partner in China

Our Pipeline: Advancing DNA Medicine

We are advancing DNA medicine candidates with the potential to transform disease prevention and treatment paradigms and improve patients' lives. In our clinical trials conducted to date, our DNA medicine candidates have been well tolerated and shown a favorable safety profile while demonstrating the ability to induce robust immune responses. They can be re-administered, allowing for their use as primary vaccinations and long-term therapies.

Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)

The FDA's review of INOVIO's Biologics License Application (BLA) for INO-3107 as a potential treatment for RRP is advancing under the accelerated approval program toward a Prescription Drug User Fee Act (PDUFA) target action date of October 30, 2026. Recent regulatory progress includes completion of the late-cycle review meeting and all scheduled pre-licensure inspections. An informal clinical meeting was conducted, where INOVIO presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, along with the company's rationale for accelerated approval eligibility. During the informal meeting, the FDA did not discuss its preliminary comment in the file acceptance letter regarding accelerated approval eligibility. INOVIO continues to believe that INO-3107 fulfills the criteria for accelerated approval by meeting an unmet clinical need and providing a meaningful therapeutic benefit over existing treatments.



*BLA accepted for review under accelerated approval program in Dec 2025 with a target PDUFA date of Oct 2026 **VGX-3100 to Apollo Bio for China

SNAPSHOT: BUILDING ON EXPERIENCE IN HPV

A growing body of clinical research points to the potential of DNA medicines to change treatment paradigms, particularly for HPV-related diseases where targeted cytotoxic T cell responses are needed to clear HPV-infected cells.



LEARN MORE: INOVIO.COM

MEDIA | communications@inovio.com
INVESTOR RELATIONS | investor.relations@inovio.com